Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162218521> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2162218521 abstract "Abstract Objectives To analyze the Spanish experience in an international study which evaluated tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor inhibitors (TNFis) in a clinical practice setting. Material and methods Subanalysis of 170 patients with RA from Spain who participated in a phase IIIb, open-label, international clinical trial. Patients presented inadequate response to DMARDs or TNFis. They received 8 mg/kg of tocilizumab every 4 weeks in combination with a DMARD or as monotherapy during 20 weeks. Safety and efficacy of tocilizumab were analyzed. Special emphasis was placed on differences between failure to a DMARD or to a TNFi and the need to switch to tocilizumab with or without a washout period in patients who had previously received TNFi. Results The most common adverse events were infections (25%), increased total cholesterol (38%) and transaminases (15%). Five patients discontinued the study due to an adverse event. After six months of tocilizumab treatment, 71/50/30% of patients had ACR 20/50/70 responses, respectively. A higher proportion of TNFi-naive patients presented an ACR20 response: 76% compared to 64% in the TNFi group with previous washout and 66% in the TNFi group without previous washout. Conclusions Safety results were consistent with previous results in patients with RA and an inadequate response to DMARDs or TNFis. Tocilizumab is more effective in patients who did not respond to conventional DMARDs than in patients who did not respond to TNFis." @default.
- W2162218521 created "2016-06-24" @default.
- W2162218521 creator A5004363203 @default.
- W2162218521 creator A5019811024 @default.
- W2162218521 creator A5028425742 @default.
- W2162218521 creator A5034211653 @default.
- W2162218521 creator A5034794166 @default.
- W2162218521 creator A5061436981 @default.
- W2162218521 creator A5066522840 @default.
- W2162218521 creator A5079268052 @default.
- W2162218521 creator A5084037939 @default.
- W2162218521 date "2014-03-01" @default.
- W2162218521 modified "2023-10-17" @default.
- W2162218521 title "Tocilizumab in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-modifying Antirheumatic Drugs or Tumor Necrosis Factor Inhibitors: Subanalysis of Spanish Results of an Open-label Study Close to Clinical Practice" @default.
- W2162218521 cites W1979364075 @default.
- W2162218521 cites W2062697678 @default.
- W2162218521 cites W2063485775 @default.
- W2162218521 cites W2097874407 @default.
- W2162218521 cites W2102207725 @default.
- W2162218521 cites W2114308202 @default.
- W2162218521 cites W2125212735 @default.
- W2162218521 cites W2128775174 @default.
- W2162218521 cites W2143875454 @default.
- W2162218521 cites W2146166312 @default.
- W2162218521 cites W2150952126 @default.
- W2162218521 cites W2169537705 @default.
- W2162218521 cites W2314052274 @default.
- W2162218521 cites W2319957449 @default.
- W2162218521 doi "https://doi.org/10.1016/j.reumae.2013.12.018" @default.
- W2162218521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24099961" @default.
- W2162218521 hasPublicationYear "2014" @default.
- W2162218521 type Work @default.
- W2162218521 sameAs 2162218521 @default.
- W2162218521 citedByCount "4" @default.
- W2162218521 countsByYear W21622185212017 @default.
- W2162218521 crossrefType "journal-article" @default.
- W2162218521 hasAuthorship W2162218521A5004363203 @default.
- W2162218521 hasAuthorship W2162218521A5019811024 @default.
- W2162218521 hasAuthorship W2162218521A5028425742 @default.
- W2162218521 hasAuthorship W2162218521A5034211653 @default.
- W2162218521 hasAuthorship W2162218521A5034794166 @default.
- W2162218521 hasAuthorship W2162218521A5061436981 @default.
- W2162218521 hasAuthorship W2162218521A5066522840 @default.
- W2162218521 hasAuthorship W2162218521A5079268052 @default.
- W2162218521 hasAuthorship W2162218521A5084037939 @default.
- W2162218521 hasConcept C126322002 @default.
- W2162218521 hasConcept C197934379 @default.
- W2162218521 hasConcept C2777178219 @default.
- W2162218521 hasConcept C2777575956 @default.
- W2162218521 hasConcept C2908564923 @default.
- W2162218521 hasConcept C2909063479 @default.
- W2162218521 hasConcept C71924100 @default.
- W2162218521 hasConceptScore W2162218521C126322002 @default.
- W2162218521 hasConceptScore W2162218521C197934379 @default.
- W2162218521 hasConceptScore W2162218521C2777178219 @default.
- W2162218521 hasConceptScore W2162218521C2777575956 @default.
- W2162218521 hasConceptScore W2162218521C2908564923 @default.
- W2162218521 hasConceptScore W2162218521C2909063479 @default.
- W2162218521 hasConceptScore W2162218521C71924100 @default.
- W2162218521 hasLocation W21622185211 @default.
- W2162218521 hasOpenAccess W2162218521 @default.
- W2162218521 hasPrimaryLocation W21622185211 @default.
- W2162218521 hasRelatedWork W1838548883 @default.
- W2162218521 hasRelatedWork W189077404 @default.
- W2162218521 hasRelatedWork W1990433881 @default.
- W2162218521 hasRelatedWork W2326212519 @default.
- W2162218521 hasRelatedWork W2795943328 @default.
- W2162218521 hasRelatedWork W2953955431 @default.
- W2162218521 hasRelatedWork W3012989600 @default.
- W2162218521 hasRelatedWork W4239841759 @default.
- W2162218521 hasRelatedWork W4254827893 @default.
- W2162218521 hasRelatedWork W2937179026 @default.
- W2162218521 isParatext "false" @default.
- W2162218521 isRetracted "false" @default.
- W2162218521 magId "2162218521" @default.
- W2162218521 workType "article" @default.